Evaluation of Macular Structural and Functional Function Following Extensive Retinal Laser Therapy in Patients With Proliferative Diabetic Retinopathy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-04-10

Study Completion Date

2019-04-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The present study is a semi-experimental clinical trial that 20 patients (40 eyes) with PDR underwent PRP with ARC with a spot number of 1,200 to 1,500 per eye and spot size 500 micron with a duration of 200 ms. The variables of contrast sensitivity, macula thickness under fovea , BCVA, the width of thyroid under fovea , RNFL thickness in the four areas around the disc, and the quality of life questionnaire of all patients were recorded at the beginning of the study.Retinal and choroid under fovea thickness and RNFL thickness were assessed in four areas, one week and one month after the end of treatment, and all the variables mentioned earlier were evaluated three months after PRP surgery.

This study is single group that the outcomes are compared before and after the intervention

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparison of Two Laser Therapy Methods for PDR

NCT01232179

Proiriftrative Diabetic Retinopathy

UNKNOWN PHASE2

Safety and Efficacy of Low-Fluence PRP for PDR

NCT01737957

Proliferative Diabetic Retinopathy

TERMINATED NA

Effect of Argon Laser Panretinal Photocoagulation on Corneal Endothelial Cell Density .

NCT07157553

Panretinal Photocoagulation

NOT_YET_RECRUITING

Macular Vessels Density Before and After PRP in Patients With Proliferative Diabetic Retinopathy

NCT04976361

PRP

COMPLETED NA

PRP vs PRP+IVC for Severe nPDR

NCT03863535

Severe Nonproliferative Diabetic Retinopathy Diabetic Retinopathy Diabete Mellitus

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention group

20 patients (40 eyes) with PDR underwent PRP with ARC with a spot number of 1,200 to 1,500 per eye and spot size 500 micron with a duration of 200 ms.

Group Type EXPERIMENTAL

Panretinal Photocoagulation (PRP)

Intervention Type PROCEDURE

PRP with ARC with a spot number of 1,200 to 1,500 per eye and spot size 500 micron with a duration of 200 ms.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Panretinal Photocoagulation (PRP)

PRP with ARC with a spot number of 1,200 to 1,500 per eye and spot size 500 micron with a duration of 200 ms.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diabetes Mellitus, Type 2 with PDR
* Having conscious satisfaction

Exclusion Criteria

* Patients with a history of other eye diseases
* Patients with a history of previous laser treatment
* Patients with a history of injection of Anti-VGEF
* Patients with Vitreous hemorrhage
* Patients with Macula edema
* Patients with myopia more than -3 diopters or hyperopiamore than +3 diopters

Eligible Sex

ALL

Accepts Healthy Volunteers

No